Resource Center
A leader in the industry, Dr. Ferrara’s career has focused on the immunology of BMT, particularly its major complication GVHD. Using innovative proteomic techniques, his team has identified and validated biomarkers for skin, gut and steroid-resistant GVHD. Eurofins Viracor is exclusively partnering with Dr. Ferrara to utilize the approach developed by Drs. Ferrara and Levine and the Mount Sinai Acute GVHD International Consortium (MAGIC).
This bi-lateral lung transplant recipient is a 65 year-old male patient who received his lung transplant due to end-stage lung disease secondary to non-CF bronchiectasis. The donor and recipient CMV serostatus is D+/R+. The patient’s initial peri-operative course was complicated by difficult explant, primary graft dysfunction, respiratory failure requiring prolonged mechanical ventilation, renal insufficiency and recurrent infectious concerns, including pseudomonas and stenotrophomonas pneumonias.